SCHEMBL755505

SCHEMBL755505

COc1cc(C(=O)O)ccc1Oc1ccc([C@@H](C)[C@@](O)(c2ccnc(Cl)c2)C(F)(F)F)c(Cl)c1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TTR P02766 2/20 0.41
TSHR P16473 3/20 0.40
CA12 O43570 1/20 0.37
CA1 P00915 1/20 0.37
CA2 P00918 1/20 0.37
CA4 P22748 1/20 0.37
CA6 P23280 1/20 0.37
CA7 P43166 1/20 0.37
TPMT P51580 1/20 0.37
CA9 Q16790 1/20 0.37
CA14 Q9ULX7 1/20 0.37
MRGPRX4 Q96LA9 2/20 0.36
PTGER4 P35408 1/20 0.35
HPGD P15428 1/20 0.35
NPSR1 Q6W5P4 1/20 0.35
GRM7 Q14831 1/20 0.34
FGFR2 P21802 1/20 0.34
KDR P35968 1/20 0.34
MAPT P10636 1/20 0.33
LPAR1 Q92633 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL733627 1.00 TTR (0.41) TTRTSHRCA12CA1CA2
SCHEMBL479833 0.92 MRGPRX4 (0.37) TTRMRGPRX4PTGER4
SCHEMBL479881 0.91 IGFBP3 (0.38) PTGER4KDR
SCHEMBL479786 0.89 PTGER4 (0.39) PTGER4KDR
SCHEMBL755439 0.88 HDAC8 (0.41) TSHRMRGPRX4HPGDMAPT
SCHEMBL479853 0.88 HDAC8 (0.41) TSHRMRGPRX4HPGDMAPT
SCHEMBL479843 0.86 PYGL (0.35) TTRKDR
SCHEMBL479841 0.85 PDK1 (0.40) TSHR
SCHEMBL733495 0.84 HRH3 (0.42) PTGER4MAPT
SCHEMBL480027 0.84 PTGER4 (0.35) MRGPRX4PTGER4KDR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8138189-B2 Substituted benzene compounds as modulators of the glucocorticoid receptor HOFFMAN-LA ROCHE INC. (US) 2012-03-20 US disclosed
US-8138189-B2 Substituted benzene compounds as modulators of the glucocorticoid receptor HOFFMAN-LA ROCHE INC. (US) 2012-03-20 US disclosed
US-20100249139-A1 1,1,1-TRIFLUORO-2-HYDROXYPROPYL COMPOUNDS HOFFMANN-LA ROCHE, INC. 2010-09-30 US disclosed
WO-2010108902-A1 1,1,1-TRIFLUORO-2-HYDROXYPROPYL COMPOUNDS F. HOFFMANN-LA ROCHE AG (CH) 2010-09-30 WO disclosed
US-20100249139-A1 1,1,1-TRIFLUORO-2-HYDROXYPROPYL COMPOUNDS HOFFMANN-LA ROCHE, INC. 2010-09-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100249139-A1 1,1,1-TRIFLUORO-2-HYDROXYPROPYL COMPOUNDS NR3C1, NR3C2, CRHR1 TTR 731/4885TSHR 94/4885CA12 4865/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.